When people start Wegovy, Ozempic or Mounjaro, the focus is usually on weight loss and blood sugar control. But many users notice something unexpected: a shift in mood, reduced cravings for alcohol or sugar, and for some, a relief from symptoms of anxiety and depression. Is this coincidence? Not at all — there is now solid research showing that GLP-1 medications affect the brain in ways that go far beyond the digestive system.

What are GLP-1 receptors in the brain?

GLP-1 is a natural hormone primarily produced in the gut in response to eating. But GLP-1 receptors are not found only in the pancreas and gastrointestinal tract — they are also present in the brain, particularly in areas that govern reward, motivation, stress and mood.

When GLP-1 medications (such as semaglutide or tirzepatide) bind to these receptors in the brain, they influence the dopamine system — the so-called reward system. This is the same system activated by food, alcohol and other substances. It explains why many users report reduced cravings for sweets and alcohol — not just because they are less hungry, but because the brain's reward signal is dampened.

GLP-1 and depression: promising results

A large Scandinavian register study published in The Lancet Psychiatry in 2026 followed more than 200,000 patients with depression or anxiety across Denmark, Norway and Sweden. The study found that patients treated with GLP-1 receptor agonists (primarily semaglutide) had significantly lower risk of worsening depression (hazard ratio 0.56) and anxiety (HR 0.62) compared to the control group.

This means the risk of depression getting worse was nearly halved in those taking GLP-1 medication. That is a remarkable finding — and it is corroborated from other angles.

A post-hoc analysis of the large STEP trials (published in JAMA Internal Medicine, 2024) investigated psychiatric safety in participants without known mental health conditions. Researchers found no increased risk of depression, anxiety or suicidal behaviour — in fact, data showed a slight positive trend in mood among those who lost the most weight.

Is the effect through weight loss — or directly in the brain?

This is an important question. It is well established that weight loss itself improves mental health: better self-image, more energy, less pain, better sleep. But research suggests GLP-1 medications also have direct neural effects, independent of weight loss.

A review published in Nature Mental Health (2025) examined 47 studies and concluded that GLP-1 receptor activation in the brain reduces neuroinflammation, influences stress hormone regulation and modulates dopamine pathways — all mechanisms relevant to depression and anxiety. These effects were also seen in animal studies, where GLP-1 agonists reduced anxiety-like and depression-like behaviour independent of body weight changes.

GLP-1 and cravings: alcohol, sugar and other habits

One of the most surprising findings in recent years is that GLP-1 medication reduces the desire for alcohol. A systematic review and meta-analysis published in eClinicalMedicine (The Lancet, 2025) analysed 14 studies with over 900,000 patients and found a significant reduction in alcohol consumption among GLP-1 agonist users.

In one randomised trial, participants taking dulaglutide (another GLP-1 agonist) were 29% more likely to reduce their alcohol intake compared to placebo. The effect is thought to stem from the medication dampening the brain's reward response to alcohol in the same way as to food.

Research also suggests similar effects on nicotine, and in animal studies on cocaine. Clinical trials of semaglutide for alcohol and substance use disorder are underway — this could prove to be one of the most significant future applications of the GLP-1 class.

Important caveats: what we don't know yet

The picture is not unambiguously positive. There are individual case reports of patients experiencing worsening depression, increased anxiety or mood swings — particularly during the start-up phase, when side effects such as nausea and sleep disturbances are most pronounced.

In 2023, the European Medicines Agency (EMA) and the FDA launched a review of possible risks of self-harm and suicidal thoughts in GLP-1 medication users, based on spontaneous reports. Subsequent large register studies have not confirmed a causal link, but this underscores the importance of vigilance — particularly in people with a psychiatric history.

It is also important to note that most studies have been conducted in people without serious mental illness. Research in patients with schizophrenia, bipolar disorder or severe depression is still limited, and findings cannot be directly extrapolated.

What if you already have anxiety or depression?

Many people who take GLP-1 medication already have a mental health condition — obesity and mental health disorders frequently co-occur. The question is whether the medication is safe, and perhaps even beneficial, for this group.

The Scandinavian Lancet study gives grounds for cautious optimism: it specifically included patients with existing depression and anxiety and still found a protective effect. But it is crucial that — before starting and throughout treatment — you talk openly with your doctor about your mental health, any changes in symptoms and any other medications you are taking.

GLP-1 medications are not approved for treating depression or anxiety, and they should not replace psychiatric treatment. But the evidence suggests that for many people they do not worsen mental health — and for some may even help.

Practical advice: what to watch for

The future: GLP-1 as psychiatric medication?

The research community is increasingly excited about the potential of GLP-1 receptor agonists in psychiatry and neurology. Clinical trials are underway with semaglutide for alcohol use disorder, Alzheimer's disease, depression and even schizophrenia.

It is too early to conclude that Wegovy is an antidepressant — but it is not too early to say that the medication influences the brain in biologically relevant ways, and that the research is promising.

Sources